The U.S. Food and Drug Administration is wrapping up the month of September with a few PDUFA dates, including an approval review of Aquestive’s Libervant for the management of seizure clusters in epilepsy.

San Diego-based Neurocrine Biosciences is partnering with Japan’s Takeda Pharmaceutical to develop and commercialize molecules in Takeda’s early-to-mid-stage psychiatry pipeline.

San Francisco-based Spruce Biosciences closed on a Series B financing round valued at $88 million, as the company develops tildacerfont for the rare genetic disorder congenital adrenal hyperplasia (CAH).